A novel solid phase synthesis of an estradiol derivative and preclinical evaluation for targeting estrogen-receptor positive breast cancer
Abstract [18F]-Fluoroestradiol, which is recently approved by the FDA, is a well-recognized estrogen receptor radiopharmaceutical in nuclear medicine to investigate both primary and metastatic breast cancers. This study introduces an innovative and effective method for synthesizing the DOTA-coupled...
Saved in:
| Main Author: | Subhani M. Okarvi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-15367-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor Ki-67, ER and PR, and antibodies against estradiol and progesterone in breast cancer patients
by: A. N. Glushkov, et al.
Published: (2023-09-01) -
Recent advances of G protein‐coupled estrogen receptor 1 in the metabolism of bone
by: FENG Yuan, et al.
Published: (2023-06-01) -
Progress of estrogen receptor and spliceosome in endometrial carcinoma
by: Ziqi Hong, et al.
Published: (2025-08-01) -
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results
by: Erika P. Hamilton, et al.
Published: (2025-07-01) -
Estrogen-Receptor Expression and Function in Thymocytes in Relation to Gender and Age
by: F. Kohen, et al.
Published: (1998-01-01)